Millennium Management’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-2,004,795
Closed -$82M – 6655
2024
Q2
$82M Buy
2,004,795
+531,972
+36% +$22.2M 0.04% 511
2024
Q1
$62.3M Buy
1,472,823
+361,711
+33% +$15.2M 0.03% 698
2023
Q4
$47.1M Sell
1,111,112
-1,018,701
-48% -$29.3M 0.02% 843
2023
Q3
$46.5M Buy
2,129,813
+1,950,018
+1,085% +$48.8M 0.02% 756
2023
Q2
$5.72M Sell
179,795
-285,195
-61% -$8.75M ﹤0.01% 2557
2023
Q1
$11.3M Buy
+464,990
New +$13.6M 0.01% 1831
2022
Q2
– Sell
-45,371
Closed -$1.29M – 7662
2022
Q1
$1.59M Sell
45,371
-15,231
-25% -$445K ﹤0.01% 4084
2021
Q4
$1.96M Buy
60,602
+48,332
+394% +$1.71M ﹤0.01% 3795
2021
Q3
$362K Buy
+12,270
New +$344K ﹤0.01% 5662
2021
Q2
– Sell
-426,016
Closed -$5.85M – 7258
2021
Q1
$5.85M Buy
426,016
+386,444
+977% +$5.65M ﹤0.01% 2404
2020
Q4
$656K Buy
+39,572
New +$514K ﹤0.01% 4008

Other funds holding CERE

Millennium Management's CERE Position: Q3 2024 in Review

Millennium Management sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2024, closing a stake of 2,004,795 shares — an estimated $82M sold.

Millennium Management first reported a position in CERE in Q4 2020 and held it in 11 quarters. The position peaked at $82M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Millennium Management reported no remaining Cerevel Therapeutics Holdings position as of Q3 2024 after selling out during the quarter.
  • Millennium Management sold 2,004,795 Cerevel Therapeutics Holdings shares in Q3 2024, an estimated $82M.
  • Millennium Management first reported a position in Cerevel Therapeutics Holdings in Q4 2020 and held it in 11 quarters.
  • Millennium Management's Cerevel Therapeutics Holdings position peaked at $82M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2024.

Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.